

Down-regulation of transforming growth factor β receptor type III in hepatocellular carcinoma is not directly associated with genetic alterations or loss of heterozygosity

HYUN JIN BAE, JUNG WOO EUN, JI HEON NOH, JEONG KYU KIM, KWANG HWA JUNG,
HONG JIAN XIE, WON SANG PARK, JUNG YOUNG LEE and SUK WOO NAM

Department of Pathology, Microdissection Genomics Research Center,
College of Medicine, The Catholic University of Korea, Seoul 137-701, Korea

Received May 5, 2009; Accepted June 24, 2009

DOI: 10.3892/or_00000459

Abstract. The transforming growth factor receptor III (TGF β RIII) is the most abundant and essential TGF- β binding protein that functions as a co-receptor with other receptors in TGF- β signaling. In earlier studies, expression of TGF β RIII was reported to be decreased in a variety of human cancers. Functional assessment of TGF β RIII was performed in many previously studied cancers but not in hepatocellular carcinoma. Therefore, in this study, we investigated the expression and genetic alterations of TGF β RIII in hepatocellular carcinoma (HCC) by quantitative real-time PCR (qRT-PCR) and single-strand conformation polymorphism (SSCP) analysis. The qRT-PCR showed down-regulation of TGF β RIII in the tumor samples. To investigate whether genetic alterations mediated decreased expression of TGF β RIII, we performed mutation analysis of 67 human HCC tissues by SSCP and direct sequencing. We found five previously reported and one novel single nucleotide polymorphisms in exons 2, 3, 5, 13 and 14, but no mutations were detected. These polymorphisms were not associated with amino acid changes except for a base change found in exon 2 (TCC→TTC, S15F). The loss of heterozygosity (LOH) analysis performed on 10 tumors and corresponding normal pairs, showed a low rate of LOH (2/10). The results of this study suggest that TGF β RIII is transcriptionally down-regulated in hepatocellular carcinoma. In addition, genetic alterations did not appear to be associated with the reduced expression level of TGF β RIII. To clarify the role of TGF β RIII in hepatocellular tumor development and progression, functional analysis is needed in future studies.

Introduction

Hepatocellular carcinoma (HCC) is the fifth most common cancer; the associated mortality is the third highest among cancers. HCC is one of the main causes of cancer-related death in Asia and Africa (1). Hepatitis B virus (HBV), hepatitis C virus (HCV) and aflatoxin B1 are well known major causative agents of HCC. However, the underlying mechanisms involved in the development and progression of HCC remain poorly understood (2). Previous studies have reported that genetic alterations of tumor associated genes such as p53, β -catenin and AXIN1 are involved in hepatocarcinogenesis (3-5); however, the frequencies of mutations in these genes appear to be very low in patients with HCC. Furthermore, it is unclear how these genetic changes precisely cause the clinical characteristics observed in individual patients with HCC. Therefore, the major molecular events underlying HCC remain to be identified.

The transforming growth factor β (TGF- β) family consists of diverse structurally related growth factors that regulate a wide variety of cellular processes including cell proliferation, lineage determination, differentiation, motility, adhesion and death (6). There are three TGF- β isoforms (TGF- β 1-3) that exert their role by binding to three types of receptors: type I (TGF β RI), type II (TGF β RII) and type III (TGF β RIII) (7). TGF- β signaling, is characterized by ligand binding to TGF β RII, continuously active serine/threonine kinase, recruitment and phosphorylation of TGF β RI (8). Activated TGF β RI transmits signaling by activating Smad 2 or Smad 3, which form a complex with Smad 4 (8,9). The Smad complex then translocates to the nucleus to activate the target genes in a cell-specific manner (6,7,9).

The transforming growth factor β receptor type III (TGF β RIII, also called betaglycan) consists of 849 amino acids with a short cytoplasmic tail that includes 41 amino acid residues (10). TGF β RIII is the most abundant TGF- β receptor; it is regarded as a co-receptor that presents ligands to TGF β RII, thought to be due to the absence of a signaling motif (10,11). There is considerable evidence implicating TGF β RIII in a variety of human cancers. Down-regulation of TGF β RIII expression has been reported in renal cell carcinoma and endometrial carcinoma (12,13). Moreover, in addition to the loss of expression, a tumor suppressing role

Correspondence to: Dr Suk Woo Nam, Department of Pathology, College of Medicine, The Catholic University of Korea, #505 Banpo-dong, Seocho-gu, Seoul 137-701, Korea
E-mail: swnam@catholic.ac.kr

Key words: transforming growth factor β receptor III, hepatocellular carcinoma, mutation, loss of heterozygosity

of TGF β RIII has been suggested in breast, prostate and non-small cell lung cancers (14-16). However, no such studies have been performed to date in human HCC. In addition, DNA micro-array data, from our previous study, indicated that the expression of TGF β RIII was gradually down-regulated from the pre-cancer state to overt cancer in HCC compared to corresponding normal tissues (17), suggesting a possible role of TGF β RIII in hepatocarcinogenesis.

Therefore, in this study, we investigated the differential gene expression of TGF β RIII in tumor and normal paired tissue samples and the genetic alterations of the TGF β RIII gene in 67 hepatocellular carcinoma cases by quantitative real-time PCR (qRT-PCR), single-strand conformation polymorphism (SSCP) and sequencing and loss of heterozygosity (LOH) analysis.

Materials and methods

Tissue samples. Sixty-seven frozen HCCs and their corresponding background normal tissue samples obtained from 67 patients at resection were evaluated. Approval was obtained from the Institutional Review Board of College of Medicine, The Catholic University of Korea and informed consent was obtained beforehand in accord with the requirements of the Declaration of Helsinki. There was no evidence of familial cancer in any of the patients. The ages of the patients ranged from 4-74 (average 55 years) and there were 48 men and 19 women. The background liver demonstrated the presence of cirrhosis in 24 (35.8%) cases, chronic hepatitis in 40 (59.7%) and no specific change in 3 (4.5%). HBV was detected in 51 (76.1%) and HCV in 4 patients (6%). Histologically, 1, 39 and 27 samples were Edmonson grades I, II and III, respectively.

Cell culture. Ten HCC cell lines, HepG2, Hep3B, PLC/PRF/5, SNU-182, SNU-354, SNU-368, SNU-387, SNU-423, SNU-449 and SNU-475 were cultured in RPMI-1640 medium (Lonza, Walkersville, MD, USA) containing 10% fetal bovine serum (Lonza) and 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA). An immortalized normal liver cell line, THLE3, was maintained in BEBM medium (Lonza) supplemented with the BEGM Bullet kit and 10% fetal bovine serum (Lonza).

DNA extraction. Frozen tissue samples were ground to a fine powder in liquid nitrogen and this powder was incubated overnight in 500 μ l of lysis buffer (5 mM Tris-Cl pH 8.0, 20 mM EDTA, 0.5% Triton X-100) containing 500 μ g/ml of proteinase K (Takara Bio Inc., Shiga, Japan) at 50°C. Eleven cell lines were lysed with the same buffer in the presence of 100 μ g/ml of proteinase K (Takara Bio Inc.). Phenol: chloroform: isoamyl alcohol (25:24:1) solution (Sigma-Aldrich Corp., St. Louis, MO, USA) was then added to each lysate and after centrifugation (15,000 rpm, 4°C, 30 min), phenol: chloroform: isoamyl alcohol (25:24:1) solution was added to the supernatants. DNA was precipitated with ethanol at -70°C and washed with 70% ethanol. The dried pellets were resuspended with 1X TE buffer (10 mM Tris-Cl pH 8.0, 1 mM EDTA).

Quantitative real-time PCR (qRT-PCR). Total RNA was isolated from frozen tissues using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. cDNA was synthesized with the transcriptor first-strand cDNA synthesis kit (Roche Applied Science, Indianapolis, IN, USA). Real-time PCR analysis was performed in a total volume of 12.5 μ l mixture containing 3 μ l of 50-fold diluted cDNA, 0.4 pM of sense and antisense primers and 6.25 μ l of iQTM SYBR[®] Green supermix (Bio-Rad Laboratories, Hercules, CA, USA). To normalize differences in the amount of total cDNA added to each reaction, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene expression was used as an endogenous control. The reaction mixture was denatured for 3 min at 95°C and incubated for 40 cycles (denaturing for 15 sec at 95°C, annealing for 20 sec at 62°C and extension for 20 sec at 72°C). The primers used in the experiment were as follows: TGF β RIII (sense 5'-ACCGTGATGGGCATTGCGTTTGCA-3'; antisense 5'-GTGCTCTGCGTGCTGCCGATGCTGT-3') and GAPDH (sense 5'-ACCAGGTGGTCTCCTCTGAC-3'; antisense 5'-TGCTGTAGCCAAATTCGTTG-3'). The PCR was monitored in real-time using an iQTM-5 (Bio-Rad Laboratories) that allowed determination of the threshold cycle (Ct) at the time exponential amplification of the PCR products began. The average Ct, from duplicate assays, was used for further calculation and GAPDH-normalized gene expression was determined using the relative quantification method described as the following: Relative expression levels normalized to GAPDH = $2^{-(\text{TGF}\beta\text{RIII Ct} - \text{GAPDH Ct})} \times 100$. The results are expressed as the mean value of duplicates.

Single-strand conformation polymorphism and DNA sequencing. Genomic DNA samples from cell lines and HCC tissues were amplified with 21 sets of primers covering all of the coding regions of the TGF β RIII gene (Table I). The PCRs were performed under conditions with 10 μ l reaction mixtures containing 10 ng of template DNA, 0.1 mM of each deoxynucleotide triphosphate (Promega, Madison, WI, USA), 1.5 mM of MgCl₂, 0.5 unit of Ampli Taq gold polymerase, 1 μ l of 10X buffer (Perkin-Elmer, Foster City, CA, USA) and 1 μ Ci of [³²P]dCTP (Amersham, Buckinghamshire, UK). The reaction mixtures were initially denatured for 12 min at 95°C, then subjected to 40 amplification cycles (denaturing for 30 sec at 95°C, annealing for 30 sec at 49-54°C and extension for 30 sec at 72°C) and a final extension for 5 min at 72°C. After amplification, the PCR products were denatured for 5 min at 95°C, in a 1:1 dilution of sample buffer containing 98% formamide/5 mmol/l NaOH and loaded onto an SSCP gel (Mutation Detection Enhancement, FMC BioProduct, Rockland, ME, USA) with 10% glycerol. After electrophoresis, the gels were transferred to 3 MM Whatman paper and dried. Autoradiography was performed using Kodak X-OMAT film (Eastman Kodak, Rochester, NY, USA). To detect mutations, the DNAs showing mobility shifts were excised from the dried SSCP gels and re-amplified over 40 cycles using the same primer sets. After electrophoresis in 2% agarose gels, the PCR products were eluted from the gels with the Qiaquick gel extraction kit (Qiagen, Valencia, CA, USA) following the manufacturer's instructions. Sequencing of the PCR products was performed by COSMO Co., Ltd (Seoul, Korea).



SPANDIDOS PUBLICATIONS primer sequences for amplifying the coding region of *TGFβRIII* gene.

Exon	Nucleotide sequence	Product size (bp)
E2F	5'-CTGAAGTGACTGGACGAGA-3'	200
E2R	5'-CCTGGGTAAACAGAGTGAAAC-3'	
E3-1F	5'-TGATCACCTTGCCCCTTTG-3'	229
E3-1R	5'-TGCAGTGC GGAGATT CAGGA-3'	
E3-2F	5'-GTTTTGTCAGGCTGTGC-3'	199
E3-2R	5'-GTTGAACCC CAGAAGAGA-3'	
E4F	5'-TTTCTGCCCTCTTTCTGTT-3'	217
E4R	5'-CCATTATGTCCTTGTGCTAAG-3'	
E5-1F	5'-AGGTTTCGATTTACAAGCA-3'	202
E5-1R	5'-TTAACAGATGTTTCVATTTCCA-3'	
E5-2F	5'-CAGCAAACCTTCTCCTTGA-3'	200
E5-2R	5'-ATTGCCTGTCATAAATCAGT-3'	
E6F	5'-CCTCAGTGGTTTGACAGATT-3'	245
E6R	5'-TCATCTCTTGT CACACTACA-3'	
E7F	5'-AACTTTCTGGCATGTAGGTC-3'	217
E7R	5'-GACATGCTCCACCAACTT-3'	
E8-1F	5'-ATTTTAGACTCATGAGTGATTT-3'	188
E8-1R	5'-GCCATTGTGTATGAAGTTAT-3'	
E8-2F	5'-CCAAATCAATAAGAGATGAC-3'	213
E8-2R	5'-GAAATGACAGTTCCCTCACT-3'	
E9-1F	5'-GGCCTGGCATCAAACACT-3'	235
E9-1R	5'-GAGCCCATCTTCTCCCTCTT-3'	
E9-2F	5'-CCGTTTCCTTTCCAGAT-3'	246
E9-2R	5'-TAGCCTCTCTTCCCTCCTG-3'	
E10F	5'-ACAGAACTGCCTGTGGG-3'	231
E10R	5'-CAAAGCTTTGTTCTGGAAAA-3'	
E11F	5'-AGGCAGAACCAACACA-3'	233
E11R	5'-ACCCCTACTGATAACAAAC-3'	
E12F	5'-CCTGTGGGTTGTTATTTCC-3'	208
E12R	5'-AAGGTCAAGGCTAACTTTCAG-3'	
E13-1F	5'-TTGTGCCTAAAGTGAAAGTG-3'	243
E13-1R	5'-TCAGCTTGCGGGATAG-3'	
E13-2F	5'-GAAATTCTACAGTCCCAAGA-3'	215
E13-2R	5'-CTAAAAATGCCAAAATAACC-3'	
E14F	5'-CCCTGATTCTGTGCTTTGT-3'	180
E14R	5'-TCTGATCGTGCCTCCC-3'	
E15F	5'-GTTTCTGCTGAGACTTTGAT-3'	164
E15R	5'-CCCAGGAGGTTTATTTTC-3'	
E16F	5'-TGATGCAGACTAACCAAAA-3'	196
E16R	5'-AAGCTGTTACCAACTCTTA-3'	
E17F	5'-TGCCTCTTTCTCTGACTCTG-3'	219
E17R	5'-TGGCAGTAGCTGAGCTGA-3'	

Loss of heterozygosity (LOH) analysis. The tumor and the corresponding normal DNA were amplified with the D1S188, D1S406, D1S435 and D1S2804 markers. PCR was



Figure 1. Heat-map of the differential expression of TGF- β and TGF- β receptors in a dysplastic HCC nodule. TGF β RIII is down-regulated during the progression of HCC. LGDN, Low-grade dysplastic nodule; HGDN, High-grade dysplastic nodule; G1-3, Edmonson grade 1-3. Red or green color indicates comparative over- or underexpression compared to the mean value of the indicated gene expression by DNA microarray data.

performed in 10 μ l reaction mixtures containing 10 ng of template DNA, 0.1 mM of each deoxynucleotide triphosphate (Promega), 1.5 mM of MgCl₂, 0.5 unit of Ampli Taq gold polymerase and 1 μ l of 10X buffer (Perkin-Elmer) and 1 μ Ci of [³²P]dCTP (Amersham). The PCR products were then denatured and electrophoresed in 6% polyacrylamide gel containing 7 M urea. After electrophoresis, the gels were transferred to 3 MM Whatman paper and dried. Autoradiography was performed using Kodak X-OMAT film (Eastman Kodak). Identification of complete absence of one allele, in the tumor DNA of informative cases, by direct visualization, was considered LOH.

Results

Aberrant regulation of TGF β RIII in HCC. Our previous findings showed that TGF- β and the TGF- β receptor family were differentially regulated during the progression of HCC (17). TGF β RIII was gradually down-regulated from a dysplastic nodule, a precancerous region of the HCC, to Edmonson grades of HCC and overt HCC (Fig. 1). To validate the findings from the microarray analysis, we performed qRT-PCR to determine the expression of TGF β RIII in 10 pairs of HCC and corresponding normal tissues. As expected, 7 out of 10 selected HCCs had significantly reduced expression compared to the corresponding normal tissues; the remaining three had mean values of down-regulation (Fig. 2).

Genetic alterations and LOH analyses of TGF β RIII. The underlying mechanism for the down-regulation of TGF β RIII was studied in the HCC samples. The genetic alterations and LOH in the TGF β RIII gene were evaluated to determine the possible mechanism involved in the aberrant regulation of TGF β RIII. We screened mutations by SSCP and direct-sequencing of 67 HCCs and 10 liver cancer-derived cell lines, as well as the normal liver cell line, THLE3. The results showed no significant mutations in any of the coding regions analyzed. However, we observed six polymorphisms in five exons that are summarized in Table II. Among these, there was one novel polymorphism, not previously identified, located in exon 13 (G2133A); however, the novel polymorphism was not associated with an amino acid substitution

Table II. Genetic alterations of *TGF β RIII* gene in HCCs and liver cancer-derived cell lines.

Exon	Nucleotide	Codon	Amino acid	Type	SNP ID	Frequency in tissues	Cell lines
2	C44T	T <u>C</u> C→T <u>T</u> C	S15F	Missense (non-synonymous)	rs1805110	TCC (1/67) TTC (66/67)	
3	A216G	G <u>C</u> A→G <u>C</u> G	A72A	Silent (synonymous)	rs2810904	GCA (20/67) GCG (47/67)	THLE3 Hep3B PLC/PRF/5 SNU-354 SNU-387 SNU-423 SNU-475
5	A519G	T <u>C</u> A→T <u>C</u> G	S173S	Silent (synonymous)	rs2306888	TCA (47/67) TCG (20/67)	SNU-449
13	T2028C	T <u>T</u> T→T <u>T</u> C	F676F	Silent (synonymous)	rs1805113	TTT (56/67) TTC (11/67)	HepG2 SNU-182
	G2133A	A <u>C</u> G→A <u>C</u> A	T711T	Silent (synonymous)	Unknown	ACG (66/67) ACA (1/67)	
14	T2247C	A <u>C</u> T→A <u>C</u> C	T749T	Silent (synonymous)	rs284878	ACT (18/67) ACC (49/67)	THLE3 Hep3B HepG2 PLC/PRF/5 SNU-182 SNU-387 SNU-423 SNU-449




Figure 2. qRT-PCR analysis of *TGF β RIII* in HCC. Ten HCC samples were selected for the experiments. GAPDH was used as an internal control. The relative expression is presented as the mean value of duplicate results. * $P < 0.05$ by unpaired student's t-test performed using MicrosoftTM Office Excel 2007 software.

(T711T). The nucleotide alterations found in exon 2 (TCC→TTC) associated with changes in amino acids were found at high rates (66/67, 98.5%).




Figure 3. Results of the loss of heterozygosity with microsatellite markers D1S188, D1S406, D1S435 and D1S2804 (N, normal; T, tumor). Arrows indicate the alleles exhibiting LOH. LOH was detected in two samples out of ten.

In addition, allelic loss at the *TGF β RIII* locus was studied with the microsatellite markers D1S188, D1S406, D1S435 and D1S2804, in ten normal and tumor sample sets analysed by qRT-PCR. LOH was observed in two samples (Fig. 3).

There is accumulating evidence indicating that *TGF β RIII* is genetically and functionally implicated in tumorigenesis. *TGF β RIII* maps to chromosome 1p32, a region frequently deleted in a variety of human solid cancers (18). In addition, many known genes that map to this chromosomal region are thought to play a role in tumorigenesis (18). For example, when *TGF β RIII* was suppressed in pancreatic cancer cells, the endothelial to mesenchymal transition-related motility and invasiveness was increased (19). In addition, aberrant *TGF β RIII* regulation has been reported to be closely related to ovarian failure susceptibility (20). For ovarian cancer, the expression level of *TGF β RIII* was found to be decreased and did not suppress ovarian cancer cell proliferation, but inhibited motility and invasion (21). Furthermore, several studies have proposed that the *TGF β RIII* gene is a potent tumor suppressor by experiments that have shown loss of expression, frequent LOH, and inhibition of cell motility and invasion in a variety of cancers including breast, prostate and non-small cell lung carcinomas (14-16). Consistent with previous results, our findings indicated that the expression level of *TGF β RIII* was gradually down-regulated during the development of HCC compared to corresponding normal tissues, implying that down-regulation of *TGF β RIII* may play a role in hepatocarcinogenesis (Figs. 1 and 2).

In many malignant cancers, it is well established that somatic mutation and/or LOH are associated with the tumorigenesis of neoplastic cells. However, our study on genetic alterations of the *TGF β RIII* gene did not show somatic mutations or a high frequency of LOH in the HCCs. These results suggest that somatic mutations and LOH are not the major causes for the down-regulation of *TGF β RIII*. There was one mutation detected in exon 2 (SNP ID: rs1805110) with an associated amino acid change; however, this alteration did not seem to be associated with down-regulation of *TGF β RIII*, since it was not tumor-specific. However, this is the first study on polymorphisms of *TGF β RIII* in HCC. The findings suggest that this genetic alteration of *TGF β RIII* in HCC may be associated with the susceptibility for liver cancer among Korean patients. In our LOH experiments, we observed two cases of LOH out of all 10 HCC samples. It is possible that LOH at the *TGF β RIII* genomic locus is associated with the reduced expression of *TGF β RIII* in HCC. However, the low frequency of LOH suggests that it is not a major cause of the down-regulation of *TGF β RIII* in HCC.

TGF- β signaling has been implicated in cancer progression among many different types of cancer including hepatocarcinogenesis (22). Several studies have demonstrated that TGF- β is overexpressed in HCC (23,24). Furthermore, elevated levels of TGF- β in the serum and urine have been shown to be closely related to a poor prognosis and tumor angiogenesis (25-27). *TGF β RII* and Smad 4 have been associated with weaker expression levels in HCC tissues when compared to adjacent normal tissues (24). In addition, disruption of TGF- β signaling through the smad adaptor ELF (embryonic liver protein) has been shown to contribute to the development of HCC in an *in vivo* model (28). Although these findings suggest that TGF- β signaling, through TGF- β receptors, may

play a role as a tumor suppressor in HCC progression and development, the involvement of *TGF β RIII* remains to be elucidated.

In summary, the results of this study showed that *TGF β RIII* was down-regulated in human HCC. In addition, six single nucleotide polymorphisms (SNPs) in five exons of the *TGF β RIII* gene were identified, among which one was not previously reported. Furthermore, loss of heterozygosity was detected at a low rate. The findings did not show that genetic alterations and LOH were associated with aberrant regulation of *TGF β RIII* in human HCC. Additional studies with functional analysis are needed to further define the role of *TGF β RIII* in hepatocarcinogenesis.

Acknowledgements

This study was supported by the Korean Ministry of the Environment via 'The Eco-technopia 21 project' and by the Korean Science and Engineering Foundation (KOSEF) via the Cell Death Disease Research Center at The Catholic University of Korea.

References

1. Bruix J, Boix L, Sala M and Llovet JM: Focus on hepatocellular carcinoma. *Cancer Cell* 5: 215-219, 2004.
2. Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. *Nat Rev Cancer* 6: 674-687, 2006.
3. de La Coste A, Romagnolo B, Billuart P, *et al*: Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. *Proc Natl Acad Sci USA* 95: 8847-8851, 1998.
4. Pang A, Ng IO, Fan ST and Kwong YL: Clinicopathologic significance of genetic alterations in hepatocellular carcinoma. *Cancer Genet Cytogenet* 146: 8-15, 2003.
5. Satoh S, Daigo Y, Furukawa Y, *et al*: AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. *Nat Genet* 24: 245-250, 2000.
6. Massague J: TGF-beta signal transduction. *Annu Rev Biochem* 67: 753-791, 1998.
7. Blobel GC, Schiemann WP and Lodish HF: Role of transforming growth factor beta in human disease. *N Engl J Med* 342: 1350-1358, 2000.
8. Wrana JL, Attisano L, Wieser R, Ventura F and Massague J: Mechanism of activation of the TGF-beta receptor. *Nature* 370: 341-347, 1994.
9. Nakao A, Imamura T, Souchelnytskyi S, *et al*: TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. *EMBO J* 16: 5353-5362, 1997.
10. Wang XF, Lin HY, Ng-Eaton E, Downward J, Lodish HF and Weinberg RA: Expression cloning and characterization of the TGF-beta type III receptor. *Cell* 67: 797-805, 1991.
11. Derynck R and Feng XH: TGF-beta receptor signaling. *Biochim Biophys Acta* 1333: F105-F150, 1997.
12. Copland JA, Luxon BA, Ajani L, *et al*: Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression. *Oncogene* 22: 8053-8062, 2003.
13. Florio P, Ciarmela P, Reis FM, *et al*: Inhibin alpha-subunit and the inhibin coreceptor betaglycan are downregulated in endometrial carcinoma. *Eur J Endocrinol* 152: 277-284, 2005.
14. Dong M, How T, Kirkbride KC, *et al*: The type III TGF-beta receptor suppresses breast cancer progression. *J Clin Invest* 117: 206-217, 2007.
15. Turley RS, Finger EC, Hempel N, How T, Fields TA and Blobel GC: The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. *Cancer Res* 67: 1090-1098, 2007.
16. Finger EC, Turley RS, Dong M, How T, Fields TA and Blobel GC: TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. *Carcinogenesis* 29: 528-535, 2008.

17. Nam SW, Park JY, Ramasamy A, *et al*: Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. *Hepatology* 42: 809-818, 2005.
18. Ragnarsson G, Eiriksdottir G, Johannsdottir JT, Jonasson JG, Egilsson V and Ingvarsson S: Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. *Br J Cancer* 79: 1468-1474, 1999.
19. Gordon KJ, Dong M, Chislock EM, Fields TA and Blobe GC: Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. *Carcinogenesis* 29: 252-262, 2008.
20. Dixit H, Rao KL, Padmalatha VV, *et al*: Mutational analysis of the betaglycan gene-coding region in susceptibility for ovarian failure. *Hum Reprod* 21: 2041-2046, 2006.
21. Hempel N, How T, Dong M, Murphy SK, Fields TA and Blobe GC: Loss of betaglycan expression in ovarian cancer: role in motility and invasion. *Cancer Res* 67: 5231-5238, 2007.
22. Martin J and Dufour JF: Tumor suppressor and hepatocellular carcinoma. *World J Gastroenterol* 14: 1720-1733, 2008.
23. Abou-Shady M, Baer HU, Friess H, *et al*: Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma. *Am J Surg* 177: 209-215, 1999.
24. Ji GZ, Wang XH, Miao L, *et al*: Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma. *World J Gastroenterol* 12: 644-648, 2006.
25. Song BC, Chung YH, Kim JA, *et al*: Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma. *Cancer* 94: 175-180, 2002.
26. Tsai JF, Chuang LY, Jeng JE, *et al*: Clinical relevance of transforming growth factor-beta 1 in the urine of patients with hepatocellular carcinoma. *Medicine (Baltimore)* 76: 213-226, 1997.
27. Ito N, Kawata S, Tamura S, *et al*: Positive correlation of plasma transforming growth factor-beta 1 levels with tumor vascularity in hepatocellular carcinoma. *Cancer Lett* 89: 45-48, 1995.
28. Kitisin K, Ganesan N, Tang Y, *et al*: Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. *Oncogene* 26: 7103-7110, 2007.